Skip to main content

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Request a Rep Referral Form
Skip to main content
Referral Form

BENEFITS OF REACHING TARGET DOSE

WHY TYVASO?
SO your patients could see a greater impact after reaching higher doses2

Exercise capacity

Patients receiving a higher dose of TYVASO achieved a 67% greater improvement in 6MWD at 16 weeks2

Graph showing meters walked based on doses.

Hodges-Lehmann analysis.

In the MMRM analysis, patients achieving 10-12 breaths had nearly double the improvement in 6MWD at 16 weeks. Change in 6MWD by dose was a prespecified subgroup analysis.3

The clinical worsening data is a post hoc analysis of data from a prespecified efficacy endpoint. Interpret with appropriate caution.

Clinical worsening

Fewer patients in the higher-dose group experienced a clinical worsening event4*

Graph showing chance of clinical worsening based on doses.

Percentage of patients experiencing an event.

Encourage your patients to achieve their highest optimal dose.1,2

6MWD=6-minute walk distance; MMRM=mixed-effect model repeat measurement.